Metformin extends C. elegans lifespan through lysosomal pathway

Abstract excerpt

Metformin, a widely used first-line drug for treatment of type 2 diabetes (T2D), has been shown to extend lifespan and delay the onset of age-related diseases. However, its primary locus of action remains unclear. Using a pure in vitro reconstitution system, we demonstrate that metformin acts through the v-ATPase-Ragulator lysosomal pathway to coordinate mTORC1 and AMPK, two hubs governing metabolic programs. We...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genetics, Aging, and Longevity in Model Organisms
• Share to Metabolism, Diabetes, and Cancer
• Share to Pancreatic function and diabetes